COPENHAGEN, May 17 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a haemophilia drug, N9-GP.
… long-acting versions of their current blockbuster recombinant proteins that could reach the market in 2015, and Novo Nordisk NVO could enter as early as 2014. We expect this--as well as competitors' experience with marketing such drugs at …
Biogen Idec and Novo Nordisk are taking aim at Baxter's Advate ..... from the likes of Biogen-Idec and Novo Nordisk over the next few years could begin ..... can be given every three days). Novo Nordisk has also filed for approval of a …
… to continue supporting the dividend payments.Lilly has been steadily losing share in the insulin market because of Novo Nordisk 's more effective marketing and the success of its long-acting and rapid-acting insulin analogs.The recent patent …
… from Lantus, the company faces additional product specific risks from upcoming competitive launches from Eli Lilly and Novo Nordisk . Sanofi's wide lineup of branded drugs and vaccines and a robust pipeline create strong cash flows and a wide economic …
Novo Nordisk A/S ( NVO ) Q1 2013 Earnings Call ..... Senior Management Board Jesper Brandgaard - Chief Financial Officer ..... Management Board, Chairman of Novo Nordisk Engineering A/S and Chairman of Novo Nordisk IT A/S Mads Krogsgaard …
PARIS, May 2 (Reuters) - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk 's new insulin.
Novo Nordisk A/S ( NVO ) Q1 2013 Earnings Call ..... Senior Management Board Jesper Brandgaard - Chief Financial Officer ..... Management Board, Chairman of Novo Nordisk Engineering A/S and Chairman of Novo Nordisk IT A/S Analysts Richard …
COPENHAGEN, May 1 (Reuters) - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.
COPENHAGEN, May 1 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, slightly raised its sales growth outlook for the full year after first quarter operating profit rose more than forecasts.